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Definitions for the purpose of 
this document 
Available/availability – a drug can be available in a 
country or community but the patient may not be able 
to access it, eg there is a stock in the pharmacy but the 
patient cannot afford to buy it, or there are no qualified 
HCWs allowed to prescribe the drug. 
Access/accessibility – is when a drug is able to reach a 
patient: a HCW is able to prescribe it; there is a stock 
from which a HCW is able to dispense it; the HCW is 
able to give the drug to the patient (transport, etc, is not 
a barrier). 
Affordability – when an accessible drug can be paid for 
by the patient and/or their family. 
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oreword F
We are pleased to recommend this significant report that 
highlights the lack of pain control currently available 
around the world. Urgent government action is needed to 
ensure that all sections of society have equal and 
adequate access to pain control. It is estimated that 100 
million people could benefit from basic palliative care 
every year. New data in this report shows that even in 
established palliative care units, patients lack access to 
pain control that they desperately need. 
This report is launched to coincide with World Hospice 
and Palliative Care Day 2007. The first World Hospice and 
Palliative Care Day took place in 2005, with more than 
1,100 events taking place in 74 countries. Archbishop 
Desmond Tutu described the day as “an important global 
event”. Activities are wide ranging from music and arts 
performances to seminars, conferences, TV 
documentaries and successful lobbying of state officials. 
World Hospice and Palliative Care Day is coordinated by 
the Worldwide Palliative Care Alliance of national hospice 
and palliative care associations. 
The secretariat for World Hospice and Palliative Care Day 
and the Alliance is provided by Help the Hospices, the UK 
charity for the hospice movement, which supports UK 
hospices in their vital work on the front line of caring for 
people who face the end of life. 
To find out more and get involved in World Hospice and 
Palliative Care Day 2007, visit www.worldday.org or 
email worldday@helpthehospices.org.uk 
For information on Help the Hospices visit 
www.helpthehospices.org.uk or for the Worldwide 
Palliative Care Alliance visit www.wwpca.net 
Dr Cynthia Goh 
David Praill 
Co Chairs – The Worldwide Palliative Care Alliance 
iv 
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With this publication Help the Hospices gives an overview 
of the widespread lack of access to analgesia. If we do 
not work together to change this, many of us will discover, 
sooner or later, what it means to need good analgesia; if 
we personally do not encounter this lack of access, we 
will watch a relative or a friend that does. 
In this publication you will find the results of a survey held 
among palliative care workers. The results picture a 
serious situation. It is noted that the survey population will 
give a positive bias of the situation, as palliative care 
workers are likely to have relatively good access to 
opioids and other analgesics compared to an average 
doctor. 
My impression, mainly derived from the per capita 
statistics of opioid consumption, is that the situation is 
even worse than that found by the survey. The differences 
between the countries with the highest consumption and 
the remainder of the countries – the large majority – are 
very wide. These statistics show that only 10 to 15 
countries have a reasonable per capita consumption, and 
even in these countries underuse for medical reasons are 
occasionally reported. 
For many people, pain is part of their daily life. Every 
minute they are reminded of it; there is no means of 
escape. We can wonder why so many people do not have 
access to analgesia and have to suffer so much pain, 
when there is an excess of opioids in the world. One 
reason is the longstanding fear of drug dependence and 
drug abuse. This fear is, in my view, unfounded. In fact, 
the relation between drug abuse/drug dependence and 
licit medical use of controlled medicines is weak. 
More importantly, our countermeasures against the 
diversion of drugs required for medical use are out of 
balance. Globally, several hundreds of millions of people 
will require analgesia at least once in their lifetime, whilst 
only a small fraction of this number misuses opioids. 
There are restrictions on the handling of opioids for licit 
medical use which aim to prevent any possibility of 
abuse. However, many countries impose stricter 
regulations than required by the drug conventions to give 
good accountability. Yet we know that the source of the 
majority of opioids used in abuse is from illicit cultivation 
and not from the medical circuit. Furthermore, we know 
that it is quite rare for licit opioid medicines to be diverted 
for abuse. Although it is important to remain on one's 
guard, we should not exaggerate but pay attention to the 
side of the balance where the feather is, and not to the 
side where the lead weight is already. 
Fortunately, the international community agrees that we 
need change. Both the UN's Economic and Social 
Council and the World Health Assembly recently accepted 
resolutions that have provided the basis for further action 
by the World Health Organization. I have pleasure to work 
on this, and to experience strong support from many 
individuals, governments and also NGOs such as Help 
the Hospices. They are in support of improving cancer 
care, HIV care and palliative care for all. 
Together we have a strong case, and together we will be 
able to make the change. 
Dr Willem Scholten 
Technical Officer 
Department of Medicines Policy and Standards 
World Health Organization 
v 
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 Introduction 1.
One essential component of palliative care is pain relief. 
Freedom from pain allows the highest quality of life 
possible for as long as possible. As we are all aware, 
pain increases distress and anxiety not only in the 
patient but also their friends and family. Pain decreases 
the ability of a patient, their friends and family to sleep, 
carry out everyday activities, work, communicate 
effectively, concentrate, resolve any conflict and 
address many of the issues which, if thought through, 
allow peace as the end of life approaches 
(ie organising financial affairs, ensuring children are 
cared for, making a will, etc). 
Access to pain relief has been promoted as an 
essential human right by the IASP, the WHO, and the 
European Federation of IASP Chapters, EFIC.(1,2) (See 
www.iasp-pain.org for details and justification). Human 
rights refers to the concept of a universal right 
regardless of legal jurisdiction or other localising 
factors, such as ethnicity, nationality and sex. 
The UN Universal Declaration of Human Rights 
conceptualises human rights as based on inherent 
human dignity. We all know from everyday experiences 
that one person’s perception and expression of pain is 
very different to another person’s. One of the essential 
concepts is to listen and believe the patient – only they 
know what the pain feels like to them. 
The right to pain relief applies to all conditions where 
pain occurs (acute, chronic non-malignant, chronic due 
to degenerative progressive disease, etc). In some 
countries/states, oral morphine can only be prescribed 
by specialist palliative care or oncology doctors 
(Mongolia, Tamil Nadu, Peru, Honduras and 
Kyrgyzstan).(3) In these areas, patients requiring pain 
relief for any other disease or condition will be denied 
access. 
For the purpose of this publication the rights of patients 
with pain and who have progressive, incurable diseases 
will be addressed. Many of the points highlighted here 
are applicable to pain relief required for all 
circumstances. 
“…in my 10 yrs experience… I have never seen a 
doctor suggest or prescribe opioids other than 
for cancer patients, and they dismiss out of hand 
suggestions to consider them for end term AIDS 
patients, or end stage patients with severe 
respiratory distress.” 
Private communication with HCW. 
1 
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ain incidence  P1.1
Pain is a common symptom of many advanced, 
potentially incurable diseases. It occurs in most cancer 
patients especially during advanced or metastatic 
disease. The prevalence of pain depends on the type of 
cancer and stage, but overall an estimated 70% of 
advanced cancer patients experience pain.(4) 
In developing countries the incidence of pain is higher. 
A South African study of AIDS patients found a pain 
incidence of 98%(5); 60% of patients present to Hospice 
Uganda (HIV/AIDS and cancer patients) with severe 
pain.(6) 
More than 50% of patients with advanced AIDS, 
heart disease, chronic obstructive pulmonary 
disease and renal disease experience pain.(7) 
In 2005: 
~ 38.6 million (33.4 – 46 million) people 
worldwide were living with HIV 
~ 4.1 million new HIV infections.(8) 
In 2002: 
~ 10.9 million new cancer cases worldwide 
~ 24.6 million people alive with cancer 
(within three years of diagnosis) 
Incidence of cancer was highest in North 
America for men and women whilst the risk 
of dying from cancer was highest in Eastern 
Europe for men and highest in Eastern Africa 
for women.(9) 
2 
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 Opioid analgesics 1.2
The majority of pain can be controlled with careful pain 
management, addressing psychological and social 
factors and using relatively inexpensive oral medicines. 
‘Strong opioids’ are crucial to provide adequate pain 
relief. The WHO recommends oral morphine as the 
‘strong opioid’ of choice. 
Within Latin America oral methadone is often used in 
place of oral morphine, owing to: 
cheaper cost 
easier availability 
additional properties (antagonises NMDA receptor) 
which means it is better at relieving some 
neuropathic pains 
excellent oral absorption 
long half-life (leads to a smaller number of doses 
taken each day compared to normal release 
morphine) 
it being safe to use in patients with renal failure 
(renal impairment is not uncommon in palliative 
care patients). 
Paracetamol +/- NSAID 
+/­
adjuvant 
‘Strong opioid’ 
(eg oral morphine, oral methadone, oxycodone, 
‘Weak opioid’ hydromorphine) 
(codeine, dihydrocodeine, tramadol) + 
+	 Paracetamol +/- NSAID 
Paracetamol +/- NSAID +/-	 +/­

adjuvant adjuvant

Step 1	 Step 2 Step 3 
WHO Analgesic Ladder: over 20 years, studies have found this to be effective in 45 – 100% of patients.(10) 
3 
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Oral morphine and oral methadone: 
are ‘strong’ opioid analgesics (pain relieving drugs);

have been proven to be very effective analgesics,

wholly or partly relieving most types of pain;

are cheap;

are both established medicines with known,

predictable and preventable side effect profiles;

have a wide therapeutic index – the range of doses

over which they can be effective without being toxic

is exceptionally large; therefore doses can be

individualised easily;

are easy to administer;

are easy to adjust (doses) for each individual and if

analgesic requirements change.

Oral morphine has been included on the WHO EML 
since 1985.(11) 
Essential medicines are intended to be available: 
at all times in adequate amounts 
in the appropriate dosage forms 
with assured quality 
at a price the individual and community 
can afford.(12) 
The WHO EML guides countries as to the drugs to 
include in their own essential medicines list, taking 
account of disease prevalence.(13) 
Essential medicines are those that satisfy the priority 
healthcare needs of the population.(12) 
Many patients are unable to access morphine,

methadone or an equivalent opioid.

Based on INCB reports, the WHO estimated in

2006(14):

80% of cancer patients have no access to 
the pain relieving drugs required 
~7% of all people in the world will suffer 
from cancer pain that can be treated, but will 
not be treated.* 
* Based on 80% of world population having no access to 
analgesia, 12% of all death causes being from cancer and 
70% of cancer patients suffering pain – (0.8 x 0.12 x 0.7) x 
100 = ~ 7%. 
4 
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 The importance of being able 1.3
to access palliative care, 
morphine and other analgesics 
At the age of 21, Mr AB was diagnosed with a giant cell 
tumour and underwent a midtarsal amputation in 1979. 
When it recurred, in 1985, he went through an above-
knee amputation. He was able to have a reasonable 
quality of life with an artificial limb until 1992 when the 
disease recurred. He was in pain; radiotherapy helped 
only briefly. 
His severe pain meant he lost his means of livelihood 
and life became a huge burden. He had to send three 
of his four children to an orphanage. 
He was one of the first patients in the Pain and 
Palliative Care Clinic (PPCS) when it opened in 1994 in 
Calicut Medical College. By then Mr AB had been in 
pain for about two years. In the PPCS he was started 
on oral morphine and other medication. His pain was 
soon relieved. PPCS found him a livelihood by installing 
a coffee-vending machine in the hospital. It brought the 
means not only to get his children back from the 
orphanage but also to allow them all to be educated. 
His disease is slowly progressive. His morphine 
requirement slowly went up to finally reach 1,000mg a 
day, and at that time a pathological fracture in his femur 
was found. Excision of the fractured bone brought 
down the pain and since 1999 (ie for the last seven 
years), his pain has been well controlled on a steady 
dose of 600mg of morphine a day. 
He is 48 now. Recently he had a single fraction of 
palliative irradiation to the stump which has ulcerated. 
He is pain free on morphine and is able to work from 
morning to evening. His eldest son has a job and the 
other children are continuing their education. 
Case study provided by Prof M. R. Rajagopal, 
Chairman, Pallium, India 
5 
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JM is 33 year old male with Kaposi’s Sarcoma, a 
cancer occurring more frequently in HIV patients. He 
has a huge woody oedematous left leg. JM was one of 
the first cancer and HIV/AIDS patients to join the Ndi 
Moyo Palliative Care programme, Malawi, in August 
2006. 
However, he enrolled with me as a patient long before 
the Centre opened. JM lives with his wife and their four 
children. They are very poor and at first JM was living in 
denial of his condition. 
JM noticed the swelling of his left leg in 1999 and went 
to traditional healers. His leg got worse. In 2000 he 
visited Salima District Hospital where Kaposis Sarcoma 
was diagnosed. As he did not get relief from his 
symptoms, he alternated between the hospital and 
traditional healers until October 2002, when a friend 
referred him to me for pain relief at the Salima Parish 
home based care clinic where I was working as a 
volunteer nurse. 
He presented with moderate burning pains, bone pain 
and extensive fungal infections. These were managed 
with amitriptyline 12.5mg bd, ibuprofen 400mg tds and 
antifungals with good effect. At this time he was tested 
HIV positive. We controlled his pain well and treated 
opportunistic infections until February 2004, when he 
developed severe pain and blisters all over his left leg. 
As a result he became one of the very first patients in 
Salima to be given morphine, which he was only able to 
access from ‘Lighthouse’ in Lilongwe (over 100km from 
his home). 
He started on 5mg of oral morphine every four hours 
with 10mg at night. He responded well and is at 
present pain free on oral morphine (7.5mg four hourly 
with 15mg at night). For a couple of months the dose 
needed to be increased to 10mg four-hourly and 20mg 
at night. Throughout he has continued to have 
ibuprofen, and since July 2004 has had free ART. 
Access to analgesia and palliative care has really 
benefited JM; he is one of very many in Malawi who 
would benefit if they were able to access it. Besides 
medical treatment, we have provided him and his family 
with emotional support and used a comfort fund to 
assist them with transport and food at times of need. In 
addition, after a long advocacy fight by us, he and his 
family now benefit regularly from food aid distributed by 
the World Food Programme. He is now happy, able to 
walk, cycle, able to take care of his family, and we 
continue to travel with them on his journey. 
Case study provided by Lucy Finch, Nurse and 
Founder of Ndi Moyo Palliative Care Centre, Malawi. 
6 
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, Mariela enk, MDCase study provided by Roberto WMr GH was 56 years old when he was diagnosed with 
. , and María Minatel, MDBertolino, MD. He was referred to the advanced colorectal cancer
undación liativa-FaPrograma Argentino de Medicina Ppalliative care team by the oncologists in June 2003, in 
, Buenos Aires, Argentina FEMEBAsevere pain. Oral morphine and adjuvant analgesics 
were started, and these controlled his pain allowing him 
to go home. He died nearly a year later at home in April 
2004. The picture shows him preparing for his family 
Christmas. 
7 
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Graph 1: Global Consumption of Morphine 
mg/capita, 2003 
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 0 
Source: International Narcotics Control Board; United Nations “Demographic Yearbook” Countries The Global Mean is calculated by adding the individual mg/capita 
By: Pain & Policy Studies Group, University of Wisconsin/WHO Collaborating Centre, 2005 statistics for all countries and then dividing by the number of countries. 
* 2001 Reporting Data 
1.4 Unavailability of opioids 
The INCB collates information detailing each country’s 
or a number of years the INCB medical use of opioids. F
has expressed concern that there is inadequate access 
to morphine and other opioids for pain relief in many 
parts of the world. The graph to the left details the 
amount of morphine used for medical reasons by a 
country divided by the population, ie the average 
medical use of morphine per person in each country. 
The huge variation illustrates how many people are 
being denied adequate pain relief – the majority (but 
not all) of these people are in developing countries. 
UN ECOSOC Resolution 2005/25 
‘Treatment of pain using opioids’ 
Medical use of narcotic drugs (opioids) is 
indispensable for the relief of pain and 
suffering. 
Morphine should be available at all times in 
adequate amounts and appropriate dosage 
forms for the relief of severe pain. 
Low national consumption of opioids is a 
matter of great concern. 
8 
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 Help the Hospices’ 2.
survey on access to
analgesics 
In 2006 Help the Hospices, through the WWPCA, 
surveyed hospices, units and HCWs providing palliative 
care within Asia, Africa and Latin America to ascertain 
their ability to prescribe and dispense pain relieving 
drugs. All the palliative care providers listed on the 
Hospice Information website, contacts from the African 
Palliative Care Society, the Latin American Association 
for Palliative Care, the Asociación Argentina de 
Medicina y Cuidados Paliativos and those known 
personally to the researcher were contacted. 
HCWs were asked about access to drugs 
recommended on the WHO EML (this is taken as the 
required minimum level of analgesics for palliative care 
– drugs which should be available at all times, in 
adequate amounts). In addition, drugs which are not 
currently part of the WHO EML but have been 
recommended to the WHO to be included in the next 
EML by an ‘expert group’ through the IAHPC were 
included.(15, 16) 
Details of the questionnaires are available from 
Help the Hospices. 
Sixty-nine questionnaires were returned – 24 from Asia, 
28 from Africa and 17 from Latin America. This 
represented a 23% return rate from email addresses 
contacted which were not returned as invalid. 
Abbreviated results are shown in graphs 2 to 16. 
Responses were from a range of types and size of 
organisations including: 
NGO networks, contacting 6,000 – 7,000 patients 

a month; 

free standing hospices with and without inpatient

beds, with average patient numbers per month

ranging from six to 1,000; 

hospice/home care teams attached to a hospital,

with average patient numbers ranging from six to

1,000 per month;

state hospitals with average patient numbers ranging

from six to 400 a month.

When looking at the results note: 
The graphs are likely to greatly ‘overestimate’ patient 
access to opioids and other analgesics when 
considering the whole region. 
Questionnaires were completed by HCWs 
specialising in palliative care. In some countries 
there are only one or two palliative care providers 
listed on the Hospice Information website. In a large 
number of countries there are no palliative care 
providers on the website. Thus, if some of the 
respondents are unable to access the essential 
drugs, it is likely that the rest of the country is unable 
to access opioids and other analgesics (with the 
possible exception of a few private clinics or 
donations). 
The questionnaire aimed to capture information from 
rural as well as central palliative care providers; thus 
there are more questionnaires from some countries 
than others – and these are the countries where 
palliative care services are more developed. 
The results, therefore, reflect reasonable access in 
some countries, but that in other countries access is 
at a bare minimum. 
Nine of the 28 questionnaires from Africa were from 
South Africa, reflecting the larger number of palliative 
care services there than in other African countries. 
Despite this, a report in the South African Sunday 
Times newspaper, October 2006(17) (with quotes from 
Gareth Morgan, the governing Democratic Alliance 
Spokesperson), highlighted how many patients still 
cannot access analgesics: 
“…over 300,000 people died each year in South 
Africa from AIDS, and many thousands more from a 
range of other incurable illnesses. It was estimated 
that only five per cent of these people had access to 
adequate palliative care, mostly those treated in the 
private sector. This neglect, which saw thousands of 
South Africans left to die with unnecessary pain and 
fear, was inhumane”. 
The 17 questionnaires from Latin America 
represented 10 countries. 
The 28 questionnaires from Africa 
represented 11 countries. 
The 24 questionnaires from Asia represented 
10 countries (with six different Indian states – 
drug laws vary between the Indian states). 
In one main regional hospital in Malawi aspirin is 
the only NSAID always available, with ibuprofen 
occasionally available and other NSAIDs ‘never 
available’. 
9 
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 Survey results: access to analgesics 2.1
Graph 2: Access to ‘weak opioids’	
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The WHO EML recommends codeine as a ‘weak 
opioid’. For the purpose of this survey dihydrocodeine 
was included as being very similar in properties, 
strength and side effects to codeine. Tramadol was 
also included as this is more readily available in some 
areas owing to the different classification by the INCB 
and hence the different levels of accountability required. 
For this reason the recent ‘expert meeting’ to advise the 
WHO on the updating of the palliative component of the 
WHO list recommended the inclusion of tramadol as a 
‘core’ drug.(16) 
Only 55% of organisations providing palliative 
care had one of the weak opioids always 
available. 
10 
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The availability of ‘weak opioids’ was markedly 
decreased in Africa compared to Asia and Latin 
America. 
In some places ‘weak opioids’ are expensive and Note: 
hence the step of using a weak opioid is substituted 
with a smaller dose of a strong opioid. This is 
acceptable practice. 
alliative Care -five per cent of African PwentyT
Services never have a weak opioid available. 
Between 25 – 35% in Latin America and Asia do 
not ‘always’ have a weak opioid available. 
11 
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% 
Oral Morphine is the ‘strong opioid’ recommended 
on the WHO EML.(13) Normal release preparations are 
preferable as they allow easier adjusting and 
individualisation of doses. 
Note: In Latin America oral methadone is 
sometimes used instead of oral morphine. 
Reasons for preference of methadone over 
morphine include: 
additional analgesic properties (antagonism

of NMDA receptor);

longer half-life (less frequent dosing);

safe to use in renal impairment;

less expensive;

less fear from patients and their families.

For 41% and 39% of palliative care providers in 
Latin America and Africa respectively, oral 
morphine is not ‘always available’, and for 18% 
and 21% respectively, oral morphine is ‘never 
available’. 
To prevent patients suffering pain it is important 
that supply is not interrupted. 
12 
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Graph 5: Access to oral methadone 
never available 
100

90

80

never available
70

60

 
50
 always available
40

30

never available
20

always available
10

always available
0

Africa Asia Latin America 
always available 
available most of the time 
available half of the time 
occasionally available 
never available 
%
In some Latin American countries oral methadone is 
used in place of oral morphine. Oral methadone has an 
advantage in some neuropathic pains owing to its 
NMDA action. Neuropathic pain is common in AIDS 
patients and can be very difficult to control. Methadone 
can be more difficult to dose and has the disadvantage 
of accumulation. Despite the high incidence of AIDS in 
Africa, methadone was not available in any of the 
palliative care units. This may also be owing to its 
negative associations following its use to help decrease 
drug abuse, in addition to factors preventing access to 
all opioids, and the worry of accumulation. Its use in 
Latin America illustrates how, after appropriate training, 
it can be used effectively and safely. The ‘expert 
advisory group’(15) recommended methadone should be 
a ‘complementary’ drug in the next revision of the WHO 
EML.(16) 
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Graph 6: Access to one or more ‘strong opioids’ 
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‘Oral or patch strong opioids’ included tablets, 
solution, normal and slow release preparations of: 
oral morphine 
oral methadone 
oxycodone 
hydromorphone 
fentanyl patches 
and an option for ‘other’. 
ethidine was excluded from the analysis as it is P
not recommended in chronic pain relief owing to 
toxicity following accumulation. 
Over 20% of palliative care providers in Africa 
can never access a ‘strong opioid’. 
-five per cent of palliative care providers in Thirty
Latin America and 25% in Asia cannot always 
access any ‘strong opioids’. 
%
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Graph 7: Access to NSAIDs	
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Graphs 7, 8, 9 and 10 illustrate the overall results for 
the availability of some of the other recommended 
analgesics. The variation in access to different drugs 
suggests multiple reasons for lack of access. 
The current WHO EML(13) includes one NSAID, 
ibuprofen.
The ‘expert committee’ has recommended to the 
WHO that the next revision of the EML should 
include two NSAIDs.(16) 
%
NSAIDs do differ in properties, effectiveness and 
side effects. It is not known how to predict which
NSAID a pain will be relieved by. 
15 
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Graph 8: Access to neuropathic analgesics 
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‘Neuropathic pains’ covers a wide spectrum: some 
respond better to tricyclics whilst others respond better 
to anticonvulsants. No significant difference has been 
shown between different tricyclic antidepressants and 
different anticonvulsants in the control of neuropathic 
pain (with the exception of increased effectiveness of 
gabapentin compared to tricyclics in post herpetic 
neuralgia).(18, 19) 
The tricyclic amitriptylline and the anticonvulsants 
carbamazepine, phenytoin and sodium valproate are 
on the current WHO EML; all have different significant 
side effect profiles and drug interactions. Note: opioids 
can also be very effective in relieving some neuropathic 
pains. Opioids can be used in conjunction with 
tricyclics, anticonvulsants and dexamethasone. 
Thirty-seven per cent of palliative care units do

not have a constant supply of any drug from the

‘anti-convulsant class’.

Nearly 30% do not have a constant supply of one

of the tricyclics.

Twenty five per cent do not have a constant

supply of dexamethasone.

Twelve per cent never have access to an

anticonvulsant.

Dexamethasone is useful for relieving a number 
of symptoms common in palliative patients 
including: 
pain – especially nerve compression pain 
and liver capsular pain 
aphthous ulcers 
raised intracranial pressure 
spinal cord compression 
intestinal obstruction 
ureteric obstruction 
large airway obstruction 
superior vena cava obstruction 
cerebral tumours 
hypercalcaemia in lymphoma 
sweating and hot flushes. 
It can also act as an: 
antiemetic 
appetite stimulant. 
The current WHO EML(13) recommends only the 
injectable form of dexamethasone; the ‘expert 
group’ advised the addition of the tablets.(16) 
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Graph 9: Access to gabapentin	
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Gabapentin was included in the recommended list of 
palliative care drugs to be added to the WHO EML.(16) 
It has not been proved to be more effective than other 
anticonvulsants for neuropathic pain (except post 
herpetic neuralgia) but is usually better tolerated, with 
fewer side effects and drug interactions. Its cost is likely 
to be a factor decreasing access. 
17 
9337 HtH Access To Pain Relief.qxd  14/9/07  10:35  Page 18
Graph 10: Access to other analgesics	
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Graph 10 illustrates the availability of some of the other 
analgesics currently on (diazepam and paracetamol), 
or recommended to be on (hyoscine), the WHO 
EML.(13, 16) Baclofen is included as it is effective for 
muscle spasm in a similar way to diazepam but has 
fewer side effects. 
Seven per cent of palliative care units never have 
access to paracetamol (acetaminophen). 
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 Why are opioids not3.
accessible to palliative
care patients? 
Help the Hospices surveyed palliative care providers to 
ask why they felt oral morphine* was not accessible to 
their patients (responses from 69 HCWs all in different 
organisations): 24 in Asia; 28 in Africa; and 17 in Latin 
America). 
Reasons for the lack of availability could be 
categorised as: 
1.	 Excessively strict national laws and regulations. 
2.	 Fear of addiction, tolerance and side effects. 
3.	 Poorly developed healthcare systems and supply. 
4.	 Lack of knowledge – HCWs, public and policy 
makers. 
* Oral morphine was used in the questions on reasons for lack of 
access, but it is assumed that many of the reasons are equally 
applicable to oral methadone and other ‘strong/step 3’ opioids. 
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 National laws 3.1
Graph 11: Factors decreasing access: laws and regulatory barriers 
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In some countries laws governing the handling of 
morphine and other controlled drugs are impractical or 
so stringent that they prevent HCWs using morphine 
when they feel it appropriate. These laws were aimed 
at preventing misuse; they were adopted prior to 
advances in knowledge about pain and opioids, and 
were not intended to block pain relief. Other surveys 
have also highlighted this.(20) 
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1. Process requires several forms, special 
licenses and/or authorisation stamps which 
are time consuming and/or difficult to 
acquire and thus deter HCWs from 
prescribing opioids. 
“Palliative care doctors have a right to prescribe 
morphine but cannot obtain it if they work in a 
hospice which is not registered in the MoH as a 
medical organisation.” 
“Drug companies are not willing to import oral 
morphine solution as they will not make enough 
profit due to spending months on legal papers.” 
“Licences are hard to obtain. You need to write 
an exam then apply for a licence.” 
“A supply of opioids is now available in the 
central medical stores but many practitioners are 
unaware, and even some of those who have the 
information have not accessed it as they are 
unwilling to follow the due process, which they 
regard as tedious.” 
“I waited nearly one and a half years to get my 
first licence to prescribe oral morphine.” 
“Licences are hard to obtain. This is to ensure 
that only genuine companies are allowed to 
import morphine as a way of ensuring that there 
is no misuse, and to ensure that the accounting 
bodies to INCB are not so many from one 
country.” 
“Bureaucracy for collecting morphine delays 
work in the hospitals and centres.” 
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2. Length of supply allowed is short requiring 
repeated journeys – which are potentially 
expensive, a long way and difficult when ill 
– and repeated consultations with already 
busy doctors. 
a. In Honduras only a three day supply of oral 
morphine is dispensed. 
b. In Malawi only three days supply of analgesics are 
dispensed. 
c. Until the recent review of Romanian law, doctors 
could only prescribe three days supply of morphine 
(for a small number of specified diseases special 
authorisation from a government consultant could be 
obtained for ‘long term prescribing’ allowing 10 – 15 
days supply on a repeated basis for three 
months).(20) 
d. In Israel, unless the doctor confirms that the patient 
lives far from a pharmacy, supply can only be given 
for 10 days at a time. Opioids are only available from 
pharmacies with Health Sick Insurance. In some 
areas there are few or no pharmacies with Health 
Sick Insurance, meaning patients have to travel a 
long way for a few days supply. In addition, if any of 
the details required are omitted by mistake, the 
pharmacist will send the patient back to the doctor, 
which, when distances are far and patients’ are ill, 
can deter patients from obtaining their drugs. 
3. A maximum dose is stipulated. This does 
not account for patient variability and the 
fact that there is no maximum dose of 
morphine. 
a. Until reviewed recently, the Romania pharmacopeia 
stipulated that no more than 60mg per day should 
be prescribed (20, 21) 
b. Drug laws in Israel state that no more than 60mg per 
day can be prescribed for non-cancer patients 
(confirmation that patient has cancer needs to be on 
prescription). 
4. Lack of HCWs qualified to prescribe 
controlled drugs. 
a. In Honduras, Tamil Nadu, Mongolia, Peru and 
Kyrgyzstan only specialist palliative care and/or 
oncology doctors are allowed to prescribe morphine. 
b. In the Philippines only doctors with two special 
licences are able to prescribe morphine. 
c. Seventeen per cent of countries/regions were 
reported to require specific licences which were hard 
to obtain before being allowed to prescribe 
morphine. 
d. In Malawi (where clinical officers and doctors can 
prescribe opioids) there is only one doctor for every 
100,000 people.(22) Prior to a recent amendment, 
Ugandan laws allowed only doctors to prescribe 
opioids; in rural communities there is only one 
doctor for 50,000 people. Therefore, most people 
are unable to access a doctor. These figures 
compared to 164 doctors per 100,000 in the UK, 
where since May 2006 specialist nurses can 
prescribe opioids in addition to doctors. 
5. Lack of HCWs able to dispense 
controlled drugs. 
a. Ugandan law allows only pharmacists to dispense 
oral morphine. In 2000 there were only 19 
pharmacists outside the capital (ie 19 pharmacists to 
cover a population of just over 21million).(23) 
b. In the Philippines only pharmacists with S3 licenses 
are allowed to dispense oral morphine. 
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ear of addiction, tolerance  F3.2
and side effects 
Graph 12: Factors decreasing access: fears of addiction, tolerance or side effects 	
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The main reasons HCWs felt that oral morphine is not 
available are owing to fears of addiction, tolerance 
and/or other side effects. In Africa over 50% felt that 
other HCWs fear their patients will become addicted if 
given oral morphine. A high percentage also felt that 
HCWs fear accusation of misusing morphine if they 
prescribe/dispense it. The reasons why these should 
not be feared are addressed on pages 30 – 33. 
“Pharmaceuticals do not want to produce their 
own morphine due to myths and ignorance.”
“Patients fear its (morphine) use, because its 
use is related with close end stage of life.”
“Patients and relatives fear use of morphine 
thinking death is near.” 
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3.3 Poorly developed healthcare 
systems and supply 
Graph 13: Factors decreasing access: 
poor access to healthcare 
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In some areas, lack of access to morphine simply 
reflects the difficulty for numerous people to access 
health facilities. The lack of HCWs able to prescribe and 
dispense opioids is discussed under ‘national laws’ 
(pages 20 – 22) This was felt to be more of a problem 
in Africa and Latin America than Asia – which is also 
reflected in the availability of some of the non-opioid 
drugs, eg NSAIDs. Comparing the availability of 
NSAIDs with the strong opioids indicates that this is 
, as access to NSAIDs is still not the only factor
. markedly higher
e are very aware that we do not provide “W
 get our eadequate pain relief for our patients. W
drugs from the local hospital and they only allow 
us basic pain analgesics. The hospital is not 
good on drug procurement, and there are often 
.” shortages so they don’t give us what we order
24 
9337 HtH Access To Pain Relief.qxd  14/9/07  10:35  Page 25
Y REPORT
AWORLD D
Graph 14: Factors decreasing access: supply and expense 
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“Only small quantity used in a year compared 
to the fees required for importation.” 
“Morphine is not available continuously. Small 
amount imported and next order placed after 
finishing and reporting previous supply. Drug 
importer does not inform the health centres 
about the arrival of the next supply. Thus there 
is a long period of drug absence because 
waiting for importing and informing.” 
“Nobody prepares morphine in the city. It is 
prepared 600km away and delivery takes two 
days. Pharmaceuticals don’t want to produce 
their own morphine… The lab preparation 
costs US$80 per litre. I have spoken to 
pharmaceuticals and in three years I have had 
no success.” 
“Small budget for health centres does not allow 
morphine to be ordered in an adequate 
quantity. Thus only small quantities are ordered 
and imported.” 
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 Expense 3.4
Oral morphine is an inexpensive drug. Slow release 
preparations can be more expensive due to patents but 
are not required to provide good pain relief. Normal 
release preparations should be inexpensive to make; 
oral solution can often be made locally very cheaply. 
However, over one billion people live on less than $1 a 
day.(24) Palliative patients often lose their ability to earn 
or grow food so that even inexpensive drugs become 
impossible to obtain.(25) 
Twenty-six per cent felt oral morphine was too 
expensive. 
Examples include: 
a. One main hospice in Zimbabwe can only access 
normal release oral morphine for half of the patients 
who require it, as it is so expensive. 
b. In Honduras morphine (and all the other opioid 
analgesics, eg oxycodone, hydromorphine, fentanyl) 
is available readily to private patients but, owing to 
expense, only rarely available to non-private patients. 
In 2004, a survey found that the relative cost of 
analgesics in developing countries was significantly 
higher than in developed countries. Another paper 
reported how the high costs of opioids in Argentina 
restricted their availability.(26, 27, 28) 
Promotion of non-generic forms (ie patented versions of 
the drug) has caused morphine to be unaffordable in 
some areas. When expensive formulations of opioids 
appear on the market, inexpensive immediate release 
morphine often becomes unavailable. Opioids are still 
poorly understood and underutilised in many 
developing countries. Promotion of expensive 
formulations disrupts the balance in their favour, as 
there is seldom any promotion or education on the 
cheaper formulations. For example, in India even at the 
moment there are institutions which have only 
sustained release morphine. There are others which 
have no morphine at all but have transdermal fentanyl, 
though the regulatory barriers are the same for both. (29) 
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 Lack of knowledge – HCWs, 3.5
public and policy makers 
Graph 15: Factors decreasing access: lack of knowledge 
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“One of the main reasons in my state is the 
paucity of doctors prescribing morphine 
because of the lack of training/interest in 
palliative care.” 
“It is simply irrational that oral morphine is not 
available in the country whereas expensive 
fentanyl patches can be made available for the 
rich patients. Lack of doctors training, 
awareness and cure orientated approach of the 
society as well as of the medical community 
makes palliative medicine an unknown field.” 
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Graph 16: Factors decreasing access: training 
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Exclusion from a country’s essential drug list implies 
lack of understanding of the value of oral morphine in 
pain relief and possibly misunderstanding of fears by 
policy makers. 
In Latin America and Asia less than 30% of the HCWs 
surveyed had pain management included in their 
professional training. However, the majority, more than 
70%, of respondents had gone on to achieve further 
training for themselves. 
As an undergraduate: 82% of HCWs in Latin 
America and 71% of HCWs in Asia had no 
training on pain or opioids. 
“There seems to be poor knowledge of palliative 
care prescribing and fear at all levels of using 
opioids even when they are available, including 
amongst specialist doctors. For example, in my 
10 years experience… when we have suggested 
using, or asked about knowledge of using, 
combinations of, for example, haloperidol/ 
hyoscine combos with or without opioids for 
terminal patients, it is negatively received.” 
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 Essential elements 4.
required to increase
availability 
Simply providing a supply of any drug will not increase 
access; a number of interlinked factors need to be 
addressed. 
4.1 Education 
Education is fundamental, ensuring that HCWs 
are aware of: 
how to diagnose pain and other symptoms; 
which analgesics to use when, in what dose, how 
many times a day, and for how long before 
reassessment; 
how to prevent and minimise side effects; 
how to access advice and share knowledge; 
how to access local palliative care facilities; 
legal requirements and what, if any, records are 
necessary;

where necessary drugs can be sourced;

dispelling ‘morphine myths’.

It also empowers patients, carers, volunteers and each 
community through knowledge: 
that pain and other symptoms can be relieved; 
of how to access palliative care facilities; 
of how to take drugs, minimise side effects, what to 
do if side effects occur (compliance is significantly 
higher when patients understand reasons for their 
medicines, and knowledge of potential side effects 
increases trust). 
A survey in Uganda illustrated how educating 
communities can increase access and allay 
fears regarding morphine.(30) 
Finally, education is the key to ensuring that palliative 
care is supported and legislation is not restrictive by 
educating policy makers on: 
what palliative care is; 
the support INCB and international treaties give to 
ensuring opioids are available for medical purposes; 
how to account for movement of opioids and 
records required; 
the importance of integrating palliative care into 
cancer and AIDS policies; 
how current laws can be improved to allow access 
whilst preventing diversion. 
Training is also vital for drug regulatory personnel and 
police, to ensure knowledge of who can possess and 
handle controlled drugs, and the records required. 
It is important also to ensure donors and NGOs are 
aware of a country’s priorities and requirements. 
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 Addressing the fears 4.2.
A number of HCWs, government officials and patients 
fear that having morphine available to relieve pain will 
lead to drug addiction (by HCWs, patients or through 
diversion to the general public). 
Dependence on a drug can be divided into: 
Therapeutic dependence – analgesics do not 
remove the cause of the pain, therefore as long as 
the pain remains (eg the tumour is still pressing on a 
nerve) the patient will require the analgesic to remain 
pain free. Thus, patients may require morphine for 
the rest of their life in order to remain pain free. 
Pharmacological dependence – the body produces 
its own pain relieving substances, endorphins, a 
certain level of which are circulating around the body 
normally. These are chemically similar to opioids. 
When a patient is given morphine regularly their 
body ‘senses’ an increase in ‘pain relieving’ 
substances and responds by producing fewer 
natural endorphins. Consequently, if a patient 
suddenly stops taking morphine, they will have a 
lower level of endorphins than they had before they 
started taking morphine. This produces withdrawal 
symptoms. A similar reaction occurs with steroids. 
This can be simply avoided by slowly reducing the 
dose in patients that have been on morphine for a 
few weeks if the cause of the pain has resolved. 
Addiction (sometimes referred to as psychological 
dependence) – this is what is feared: abnormal, 
compulsive behaviour, including a desperation to 
obtain the drug in order to experience its psychic 
effects, characteristically having continued use 
despite harm. 
Studies show addiction or psychological 
dependence is extremely rare when opioids are 
used for pain.(31, 32, 33) 
Availability for medical use does not go hand-in­
hand with diversion for illegal purpose.(34) 
Twenty-one per cent of respondents felt that their 
colleagues fear that patients will become tolerant to 
morphine, resulting in the need for higher and higher 
doses to relieve their pain so that perhaps when pain 
becomes very severe morphine would no longer be 
effective. This can cause HCWs to delay starting 
morphine and other opioids, reserving them for 
‘exceptionally severe pain’. 
Once a patient is on the correct dose of opioid to 
relieve a pain, the dose will not need to be increased, 
unless the illness progresses, causing further pain, or 
there is another source of pain or other factors increase 
the pain (social, spiritual, psychological). Then, when 
this pain is controlled, the dose will be kept stable 
again. It is also important to explain to patients and 
relatives that: 
the pain may not become worse;

not all pains are 100% responsive to morphine, but

there are other types of analgesics which can be

tried.

“Morphine should not be withheld until the pain 
becomes unbearable.” 
Note: a patient’s pain requirement may increase even 
when there is no sign of disease progression. 
Pain is not only physical; psychological, spiritual and 
social factors impact on pain intensity. 
Pain may not be solely due to the ‘main disease’. 
Disease progression may not be easy to detect. 
In addition, remember: 
There is also no maximum dose of morphine. The 
dose should be increased to that required to relieve 
pain. 
Different pains respond to different analgesics. 
Some pains are only ‘partly’ responsive to opioids. 
Different opioids have different binding efficacies to 
different receptors, and therefore different analgesic 
properties and side effects.

Everybody has different pain thresholds, and

express and cope with pain in different ways.

“Only the patient knows how intense and frequent 
a pain is – a pain is what the patient says it is.” 
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Dispelling the fear of tolerance: 
Ms CD, a 54 year old Argentinean nun, has had a 
locally advanced phaeochromocytoma with lung 
metastases since 1997. In November 1997 she was 
referred to the palliative care team and started with 
30mg a day of immediate release morphine. In August 
1998 the morphine was changed to 15mg a day of 
methadone. Until August 2006 her disease has been 
stable, and her pain well controlled. She now receives 
10 mg a day of methadone. 
During eight years on methadone she has had a very 
active life in her religious community; she is able to 
travel and performs several daily activities. 
Case study provided by Dr Mariela Bertolino, Dr 
Roberto Wenk and Dr Guillermo Mammana, from the 
Palliative Care Unit , Tornu Hospital-FEMEBA 
Foundation. 
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Ms EF had advanced nasopharyneal cancer. She 
received oncology treatment and was referred to the 
palliative care services in March 2003 with severe pain. 
The palliative care team started her on 12mg a day of 
methadone plus adjuvant analgesics. Her pain was well 
controlled, allowing her to enjoy two more years of 
active life. Here she is pictured with her husband, 
members of the palliative care team and two tango 
dancing teachers. She died at home in May 2005. At 
this time she was on 3mg of oral oxycodone PRN, 
(usually taken twice a day) plus adjuvants. 
Case study provided by Roberto Wenk, MD, Mariela 
Bertolino, MD, and María Minatel, MD. 
Programa Argentino de Medicina Paliativa-Fundación 
FEMEBA, Buenos Aires, Argentina 
Thirty-eight per cent of respondents felt that fear 
side effects limited the use of oral morphine. 
All drugs have side effects. The side effects of morphine 
and other opioids are known and can be easily 
minimised. 
One side effect which many fear is respiratory 
depression – tolerance occurs to respiratory depression 
so that when the dose of morphine is increased 
gradually, respiratory depression does not occur. It is for 
this reason that patients are started on smaller doses of 
morphine which are titrated up until the pain is relieved 
(not because the patient has become tolerant to the 
pain relieving properties). In addition, pain is a 
respiratory stimulus, so the respiratory depressive effect 
is ‘cancelled out’ when morphine is used to relieve pain. 
Other side effects such as sickness and drowsiness can 
also be minimised by increasing the dose slowly. 
Tolerance to the constipating effect of morphine does 
not occur but can be anticipated and prevented using 
laxatives. 
Not all patients will experience side effects 
The following case study illustrates clearly how opioids do 
not render patients permanently drowsy, nor impair 
cognitive skills, nor are only used near the end of life – 
but how they can greatly enhance the life of the patient 
and their family. 
Mr JK was a surgeon from Eastern Europe 
diagnosed with disseminated cancer of the 
oesophagus. On diagnosis he was given some 
palliative chemotherapy. Initially he experienced 
severe pain which limited him in his activities. 
Following referral to the palliative care team for 
pain control, his pain was controlled very 
satisfactorily with a 50 microgramme fentanyl 
patch and occasional immediate release 
morphine for breakthrough pain. Control of his 
pain allowed him to return to work, where he 
was able to perform operations. Sadly he 
passed away at the end of 2006, but until then 
he was very busy attending meetings 
throughout the country, giving short lectures as 
well as enjoying weekends away with his family. 
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How side effects can be managed: 
Ms HI was a patient with ovarian carcinoma who was 
treated for four years by the palliative care team, after 
discontinuing chemotherapy. She had three 
enterocutanea fistulas during these years and severe 
abdominal pain related with the progression of the 
disease. 
Her pain was soon controlled with opioids. 
Unfortunately, she initially experienced some 
neurotoxicity, but the palliative care team managed this 
successfully by rotation of class and doses of different 
opioids (morphine, oxycodone and methadone). 
Successful control of her pain and the side effects

meant she was able to greatly enjoy many parts of the

next four years. She had an active life, she developed

work projects and most importantly was able to take

care of her two daughters. She was also able to

undertake long-distance trips for some months to Spain

to see one of her sisters. 

Ms HI died in the palliative care unit in 2005, having

developed brain metastases.

Case study provided by Dr Mariela Bertolino, 

Dr Roberto Wenk and Dr Guillermo Mammana, from 

the Palliative Care Unit , Tornu Hopital-FEMEBA

Foundation.
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 Accountability 4.3.
Opioids are regulated under the 1961 UN Single 
convention on Narcotic Drugs (amended by the 1972 
and 1988 protocols). The purpose of the regulation is to 
guarantee their availability for medical purposes, whilst 
preventing abuse. The INCB monitor implementation of 
the conventions. The INCB requires each country to 
submit: 
an estimate of the quantity of each specified drug 
(including opioids) it will require for medical use – 
the amount imported or produced by a country 
should not exceed its agreed annual estimate; 
quarterly forms detailing the medical use of the

specified drugs (including opioids) within the

country.

Time, resources and definition of responsibilities needs 
to be made within the drug regulatory authority for 
these activities, and to ensure accountability throughout 
the handling of these drugs. 
Factors limiting access to opioids include: 
fear by government officials and/or HCWs that 
opioid abuse will occur; 
fear by HCWs that they will be accused of abusing 
opioids if they handle them. 
By keeping accurate records of the movement of 
opioids and other restricted drugs, these worries can 
be dispelled and the INCB requirements fulfilled. It is 
recommended that records: 
are easy to complete; 
are kept throughout the whole supply chain 
(importation to patient supply or destruction or 
returned); 
include details of:

quantities acquired (imported/from

wholesaler/main hospital)

supplier (eg wholesaler/doctor) 
amount dispensed or supplied 
whom it was dispensed/supplied to 
separate running balance of the amount in 
stock for each form and strength kept (this 
should be verified with a regular physical 
count of the stock). 
Seventy-five per cent of HCWs responded that they 
kept some form of record of handling morphine in their 
practice. Standardisation and provision of record books 
from a central government level, the INCB or the WHO 
would simplify this process. 
HCWs should advise drug authorities how significant 
changes in palliative care services might alter the 
national requirements for morphine and other stipulated 
drugs. When estimating increases consider: 
the number of new patients likely to access the 
service(s); 
the percentage of these likely to require morphine 
(or other drugs); 
the average dose of morphine any patient requiring 
morphine is likely to require. 
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 Reviewing laws and policies 4.4.
Policy change will only occur if governments 
understand the importance of palliative care and the 
need to increase access to drugs for palliative care 
within their country. Thus, before changes to laws and 
policies can be addressed there is a need to: 
promote the benefit and role of palliative care,

highlighting how many patients within the country

could benefit;

ensure all government individuals are aware of the

ability of inexpensive medicines to relieve pain in the

majority of people, including children;

document areas where the requirement for palliative

care is not met;

develop leadership: workers within palliative care

who are willing to help affect change.

National drug laws vary between countries. Drug laws 
need to be relevant and practical to clinical practice. 
For example, the drug laws were amended in Uganda 
recently to allow specialist palliative nurses as well as 
doctors to prescribe oral morphine, as the number of 
doctors would not allow access to all patients requiring 
pain relief. 
There is a need to ensure palliative care is integrated 
into national HIV/AIDS and cancer policies, countries’ 
EMLs and treatment guidelines (and that all these 
include children). 
A recent INCB meeting called for relevant country 
authorities to consider and modify any restrictions in 
place which are not required by international law and 
which would potentially restrict access for medical 
need. (35) 
The PPSG has developed methods for evaluating 
national drug policies’ suitability to allow access to 
opioids for medical purposes whilst maintaining 
regulation, in cooperation with the WHO, palliative care 
experts and government regulators. A tool has been 
published in conjunction with the WHO (2000) – 
Achieving balance in national opioids control policy: 
guidelines for assessment.(36) Details of this and further 
information on amending drug laws can be obtained 
from www.painpolicy.wisc.edu 
“…consensus among all governments that the 
medical use of narcotic drugs continues to be 
indispensable for the relief of pain and suffering 
and that adequate provision must be made to 
ensure the availability of narcotic drugs for 
such purposes.”(37) 
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 Strengthening health facilities 4.5
Strengthening of many countries’ health services is 
required to enable full access to palliative and other 
drugs. It is likely that different structures and 
approaches will work better in different countries. 
It is recommended when establishing or expanding 
services to: 
examine existing services, their effectiveness and

disadvantages;

ensure integration with existing models;

encourage community participation;

ensure cooperation with the private sector;

communicate clearly to donors what is required.

 Human resources 4.5.1
Lack of trained HCWs contributes to inaccess to 
palliative drugs in a number of countries. The number 
and skill mix of HCWs varies widely between countries. 
Ways in which to address this problem will also vary, 
perhaps, for example, utilising and paying lay 
counsellors, ensuring quality training and support of 
volunteers, and establishing guidelines nurses can 
follow, with a referral doctor available. 
 Drug procurement 4.5.2
Ensuring a reliable, timely, quality and inexpensive drug 
supply is important to ensure patients remain pain free 
and prevent withdrawal reactions. Accounting for opioid 
use will help estimate quantities required. There are a 
number of steps in the drug procurement process: 
Planning – ensuring sufficient supplies are always 
available but that stock does not expire, ascertaining 
what is the best form to use, finding a reliable 
importer or supplier, co-ordination with other 
organisations (it is often more cost effective to have 
a central source therefore collaboration is important). 
Importation – sufficient time needs to be given to 
allow for form filling and potential delays, and good 
communication between clinicans and procurement 
‘agents’ is vital. 
Manufacture – is it cheaper to manufacture locally or 
in-house; who nearby has the capacity? Is the final 
formulation cheaper to import? For small scale 
manufacture (production of drugs from raw materials 
in your health facility) you will require: 
reliable source of raw materials;

good water supply;

accurate weighing scales and measures;

funnels, bowls, pestle and mortar;

labels;

containers for final product;

verified formula;

trained staff;

appropriate storage for raw materials and

final product;

quality control procedures in place.

Transportation – who is allowed to collect controlled 
drugs from a wholesaler? 
36 
9337 HtH Access To Pain Relief.qxd  14/9/07  10:35  Page 37
WORLD DAY REPORT

 Drug costs 4.5.3
Establishing a reliable, quality assured and inexpensive 
drug supply and distribution is not always easy. 
Many pharmaceutical companies are not interested in 
manufacturing morphine or in obtaining a licence for 
their formulation in countries where usage is thought to 
be low and bureaucracy potentially cumbersome. 
Perhaps there should be a call to the WHO to establish 
reliable and inexpensive manufacturing of drugs on the 
WHO EML? 
Morphine solution can be made cheaply from the 
powdered form. However, many smaller providers lack 
the scales, raw materials and qualified staff; only 32% 
of the respondents worked in units which had facilities 
for making morphine solution from the powder and then 
storing it in a secure place. Hence, establishing in-
country central production and adequate distribution 
can be a good option. In some places a larger hospital 
or NGO organisation has agreed to manufacture 
morphine solution as a central supplier. 
For example: 
In Uganda in 2000 following advocacy by Hospice 
Uganda, the MoH commissioned a charitable 
procurement and manufacturing facility to produce 
morphine solution which could be distributed to 
hospitals, health centres and palliative care 
providers as requested. Commercial manufacturers 
had been approached but owing to the lack of profit 
they were not interested in manufacturing morphine 
solution. 
In Nigeria supply of morphine through central 
importation had been erratic since 1993. Following 
advocacy by the Society for the Study of Pain and 
the Centre for Palliative Care, the University College 
Hospital pharmacy in Ibadan now prepares oral 
morphine from the morphine powder (5mg/5ml and 
50mg/5ml) and supplies patients across the country 
(with over 130 prescriptions per month being 
dispensed for cancer patients from all over the 
country). 
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 Recent advances in 5.
increasing access to
analgesics 
Over the last 10 years access to analgesics has 
increased substantially in a number of countries or 
regions within a country. A few of these are outlined 
below (this is not a comprehensive list). 
 Individuals 5.1
Numerous individuals have made significant steps 
in increasing patient access to analgesics in the last 
10 years. 
“I am instructor at the residence of general 
medicine in the hospital where I work, and I train 
residents annually in the formation of general 
palliative care, especially in the treatment of pain 
and opioid use. This has generated some 
changes for the better. Furthermore, I produced a 
basic guide that deals with the process of pain 
treatment and use of opioids, which is starting to 
be used by doctors and nurse interns, and 
hospital guards. We are currently creating a 
palliative care team.” 
 WHO and INCB 5.2
In 2005 the World Health Assembly (WHA) and 
ECOSOC adopted resolutions inviting the INCB and the 
WHO to examine the feasibility of assisting in projects 
to increase the availability of opioid analgesics 
(resolutions ECOSOC 2005/25 and WHA58.22). The 
INCB and the WHO agreed that the WHO would act as 
the focal point, with the WHO preparing the ‘Access to 
Controlled Medications Programme’. The programme, 
which will commence in late 2007 or 2008, aims to work 
with all involved, including governments and NGOs, 
addressing the situation in over 150 countries with bad 
or no access. 
The PPSG has published 22 translations of the WHO 
publication Achieving balance(36) which provides a 
resource for governments and HCWs to evaluate and 
improve national laws on preventing access to opioids. 
www.painpolicy.wisc.edu 
 Resolutions advocating for an 5.3
increase in accessibility to opioid 
analgesics 
ECOSOC 2005/25 – On treatment of pain using 
opioid analgesics. 
WHA 55.22 (25-05-2005) on Cancer prevention and 
control 
“...to examine jointly with the International Narcotics 
Control Board the feasibility of a possible assistance 
mechanism that would facilitate the adequate 
treatment of pain using opioid analgesics”. 
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 Changes in national laws 5.4
1. In February 2002 the PPSG, the Eastern European 
regional office of the WHO and the Open Society 
Institute (OIS) conducted a workshop on ‘Assuring 
the Availability of Opioid Analgesics for Palliative Care 
within Eastern Europe’. From this, Bulgaria, Croatia, 
Hungary, Lithuania, Poland and Romania completed 
action plans to help address regulations which 
impeded access. Romania was chosen as a pilot 
country. 
Hospice Casa Sperantei in Romania was 
commissioned by the Romanian MoH to review their 
opioid legislation and policy using the WHO 
guidelines. Recommendations were presented to the 
MoH in 2003 which would help increase access to 
opioids for patients, eg increasing the supply of 
opioids allowed to be given to patients from three 
days to 30 days. The recommendations were 
accepted and the new law, nr 339/Nov 2005, has 
been in action since July 2006, although it needs to 
be printed in the official journal before the regulation 
can be applied.(20, 38) 
2. In Kerala, India, advocacy and amendment of state 
drug regulations laws now allows more than 100 
palliative care units around the state to have access 
to oral morphine. An audit demonstrated that 
increased use of oral morphine did not lead to 
diversion and misuse.(34) 
3.The Ugandan Government has recently amended 
drug laws to allow clinical officers and nurses who 
have completed a specialised course in palliative care 
to be able to prescribe oral morphine.(39) This follows 
the recognition of the shortage of doctors within the 
country. Zimbabwe also allows specifically trained 
nurses to prescribe oral morphine and the 
Democratic Alliance Government in South Africa has 
recently proposed that prescribing by specially 
trained nurses should be allowed in South Africa 
too.(17) 
4.The PPSG has documented recent changes in laws 
aimed at improving access to morphine; these 
include increasing the length of supply which can be 
prescribed and dispensed: 
1. 	France: 1995 
Seven days increased to 28 days 
2. 	Mexico: 
Five days increased to 30 days 
3. 	Italy: 2001 
Eight days increased to one month; 
in addition simplified prescription format and 
allowed two drugs or dosage units on one form 
4. 	Germany: 
One day increased so there is no limit 
5. 	Peru: 
One day increased to 14 days 
6. 	India: 
Five licenses required decreased to two licenses 
for morphine 
9. 	Romania: 
Three days supply increased to 30 days supply 
10. 	Colombia: 
10 days increased to 30 days (for strong opioids) 
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 Some regional initiatives 5.5
1. Pallium India (Trust), working with the PPSG and the 
National Cancer Institute (USA), has facilitated the 
creation of palliative care facilities in three cancer 
centres in three states, in which effective palliative care 
facilities did not previously exist. Working with the 
American Cancer Society and International Network for 
Cancer Treatment and Research, the trust has also 
catalysed the development of a palliative care training 
centre in Hyderabad. 
2. Hospice Africa (Uganda) has been running a 
programme to help train HCWs in other African 
countries and help approach government officials and 
advocate the need for palliative care and morphine. To 
date, visits/courses for African countries have been 
held in Ethiopia, Tanzania, Malawi, Nigeria, Kenya, 
Ghana, Zambia, and for South Africa in Kampala and 
Uganda. Funding has come from the RAF (UK) grant 
and the Diana, Princess of Wales Memorial Fund. 
3. The African Palliative Care Association (APAC) 
provides advice on the provision of affordable, culturally 
appropriate palliative care throughout Africa. Initial visits 
to Sierra Leone (2005) have led to advice to small 
initiatives as well as discussion with Ministry officials as 
to the importance of palliative care. APCA is currently 
working in collaboration with the PPSG to help a 
number of African countries examine their drug laws, to 
ensure they allow access. In 2006 a workshop was 
commissioned to help establish country plans and 
examine drug regulations. 
info@apac.co.ug; www.apac.co.ug 
4. Help the Hospices runs a Twinning programme for 
Hospices – a two-way sharing of ideas and 
experiences. See 
www.hospiceinformation.info/hospicesworldwide/twinning.asp 
 Some country initiatives 5.6
 India 1.
In 2005 the government of India appointed a task force 
of experts to assist it in formulating a strategy for the 
country’s National Cancer Control Programme, a five 
year plan which is due to commence in 2007. The task 
force consisted of separate groups each for an 
individual area in cancer control and care. One of these 
groups was on ‘Palliative Care and Rehabilitation’. The 
group had extensive discussions via email and met a 
couple of times. Its recommendations, which were 
submitted to the government in May 2006, included 
strategy for: 
the creation of palliative care facilities, or upgrading 
them where they existed, in all of 28 Regional 
Cancer Centres in the country; 
the upgrade of five centres to training centres; 
the creation of 100 other palliative care facilities in 
other oncology centres so that each state would 
have at least two palliative care services; 
the inclusion of palliative care in undergraduate 
medical and nursing curriculum, and in the 
postgraduate curriculum for oncology trainees; 
the simplification of narcotic regulations in all 

states in India (currently 15 of 28 states have

complicated rules);

community participation in palliative care delivery. 
 Romania 2.
Hospice Casa Sperantei in Romania: 
has prepared a training curriculum (20 hours) and 
has educated 40 trainers to run a national training 
programme in the use and prescribing of opioids. 
This was funded by Help the Hospices and the 
Open Society Institute, New York; 
under the umbrella of the national postgraduate 
training centre, is running courses for doctors and 
pharmacists detailing the use and prescribing of 
opioid medication in 30 districts of Romania, in order 
to facilitate the implementation of the new opioid 
legislation. This is funded by the Open Society 
Institute New York and three drug companies: 
Janssen, Lannacher and Mundipharma. 
cshospice@hospice.bv.astral.ro 
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 Nigeria 3.
Professor Olaitan Soyannwo and four colleagues from 
Ibadan began advocating for opioid availability in 1996. 
Their dedication and enthusiasm over the last 10 years 
has led to: 
the establishment of the Society for the Study of 
Pain, Nigeria (a chapter of the International 
Association for the Study of Pain); 
the creation of the Centre for Palliative Care, Nigeria. 
Their inspiration has led to individual and group 
initiatives including: 
a home based palliative care service (supported by 
Hospice Africa, UK); 
training workshops; 

setting up a pain/palliative care clinic; 

the development of the National Palliative Care

Guidelines adopted in 2006 by the Federal Ministry 
of Health (including the use of the WHO analgesic 
ladder and opioids for severe pain); 
the inauguration of a consultative committee for 
cancer care (including a sub-committee on palliative 
care) into the Nigerian MoH in October 2006. 
Formation of this committee has allowed Professor 
Soyannwo to guide other committee members about 
how their hospitals can access opioids; prior access 
was denied in many hospitals owing to a lack of 
knowledge about how to access opioids; 
symposia for healthcare practitioners;

inclusion of palliative care and safe use of

analgesics in undergraduate and postgraduate 
teaching, and input into curriculum review; 
the dissemination of information about opioid 
accessibility and safe use through the Nigerian 
Society of Anaesthetists, the West African college of 
Surgeons annual conferences, and in-service 
training units of hospitals, eg resident doctors, 
nursing, HIV and cancer centers. 
4. Uganda 
Dr Anne Merriman and dedicated colleagues set up a 
hospice in Kampala in 1993 after ensuring the 
government would allow oral morphine to be used for 
pain relief. Hospice Uganda has expanded and now 
includes three centres in Uganda, as well as serving as 
a model Hospice for Africa and aiding other African 
countries in establishing palliative care facilities. 
Projects and initiatives include: 
three centres providing home care service for

approximately 900 patients at one time;

certified in-country training for healthcare

professionals in palliative care, currently working

closely with MoH to ensure training in all districts;

providing special training for clinical officers and

nurses to lead palliative care units in their hospitals

or teams. These nurses and clinical officers are

allowed to prescribe morphine following a recent

change in Ugandan law;

certified in-country training for volunteers in palliative

care;

training of trainers courses;

advocacy leading to: 
the inclusion of palliative care as an essential 
component in the MoH five year strategic 
plan in 2000 – this in turn led to increased 
access to oral morphine and amendments to 
Ugandan laws to allow specially trained 
clinical officers and nurses to prescribe oral 
morphine; 
the inclusion of palliative care training in 
professional undergraduate courses. 
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 Proposed projects 5.7
PPSG, a WHO collaborating centre: 
Internet courses on international pain policy. 
International Pain Policy Fellowship. 
New opioid statistics to allow the study of 
consumption (use) for medical purposes and 
estimated requirement: 
to aggregate opioids for severe pain into 
one number (ie combine figures for use of 
oral methadone, oral morphine, oral 
oxycodone etc); 
to estimate minimum country needs based 
on mortality. 
Guidance as to the essential elements of a 
balanced national drug law. 
Opioid availability profile for every country. 
Provision of support by international experts: 
speaker support 
data 
collaboration. 
 Educational 6.
opportunities 
1. Hospice Uganda – postgraduate multidisciplinary 
diploma in palliative care 
2. Pallium Latinoamerica – distance learning advanced 
course in palliative care (multidisciplinary, 
postgraduate course in Spanish) www.pallium.org 
3. Wisconsin fellowship 
4. Programa Argentino de Medicina Paliativa-Fundación 
FEMEBA, Buenos Aires, Argentina – one hundred 
and sixty hours face to face (70% clinical practice in 
palliative care units) postgraduate courses in 
palliative care for physicians, nurses and 
psychologists. E-courses for physicians and 
nurses.(40) Both activities are in Spanish 
(paliativo_femeba@arnet.com.ar) 
5. The IAHPC website details a number of other 
diplomas and courses in palliative care ­
www.hospicecare.com/edu 
 What you can do 7.
 Advocacy 7.1
Governments 
HCWs 
Public 
Call for provision of reliable and inexpensive source 
of EML drugs 
 Education 7.2
Support initiatives 
 Support for hospices through 7.3
international organisations and 
directly 
Volunteering

Financial

Coordination of services

 Research 7.4
How to increase access, demonstrating diversion is 
not a problem. 
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Achieving balance in national opioids control policy: 
guidelines for assessment 
World Health Organization, 2000: 
www.painpolicy.wisc.edu/publicat/00whoabi/00whoabi.htm 
Cancer Pain Relief 
A quarterly WHO newsletter: 
www.whocancerpain.wisc.edu 
Help the Hospices website 
Includes on-line education material, an international 
section and information on grants available: 
www.helpthehospices.org.uk 
Hospice Information 
An international resource on hospice and palliative 
care provided by Help the Hospices and 
St Christopher’s Hospice offering: 
Networking at regional, national and international 
levels 
Access to resources and training 
Electronic and print publications including: 
Worldwide Hospice and Palliative Care Online, 
Hospice Information Bulletin, 
International palliative care directories 
‘Starter packs’ for people who wish to establish a 
service or develop links through volunteer 
placements or twinning partnerships 
www.hospiceinformation.info 
International Association for Hospice and Palliative 
Care website 
Containing: 
Free monthly newsletter 
Under resources (not a comprehensive list): 
Educational resources 
Pain and palliative care assessment and 
research tools 
Policy and advocacy tools 
Standards for palliative provision 
Treatment guidelines 
Information for patients and relatives 
Administrative and programme 
development tools 
www.hospicecare.com 
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International Narcotics Control Board website 
Containing: 
UN conventions relating to opioids 
Reports: Technical reports, Treaty Adherence, 
National Estimates 
List of drugs and substances covered by the 
conventions (‘Yellow List’) 
Guidelines for National Competent Authorities 
Forms required by INCB regarding opioids 
Guidelines for travellers 
Training materials: 
Part 1 – general information 
Part 2 – estimates system 
Part 3 – statistical returns 
www.incb.org 
Médecins sans Frontières (MSF) 
MSF’s is campaigning internationally for greater access 
to essential medicines. Website includes press 
releases, reports and publications: 
www.accessmed-msf.org 
Pain and Policies Study Group, Wisconsin 
Resources on opioid availability, conference 
presentations and monographs: 
www.painpolicy.wisc.edu 
Palliative Care Matters 
Includes links to International palliative medicine 
journals and an electronic version of the Palliative 
Medicine Handbook by Ian Back: www.pallcare.info 
palliativedrugs.com 
Promotes and disseminates information about the use 
of drugs in palliative care: www.palliativedrugs.com 
WHO Expert Committee on Drug Dependence – 
Thirty-fourth report 
WHO, 2006: 
www.who.int/medicines/areas/quality_safety/34thecddm 
eet/en/index.html 
WHO List of Essential Medicines 
Includes concept of essential medicines, current 
list, guidelines and how to submit suggestions for 
future lists: 
www.who.int/medicines/services/essmedicines_def/en/ind 
ex.html 
WHO webpage on substances under international 
control, which links to UN conventions relating to 
opioids 
www.who.int/medicines/areas/quality_safety/sub_Int_co 
ntrol/en/index.html 
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